Cytokinetics Inc. (CYTK) Valuation
Historical valuation analysis based on 500 data points (2024-09-24 to 2026-09-22)
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential...
Cytokinetics Inc. (CYTK) currently trades at a P/S ratio of 0.08 (range: 0.05–0.31, 33th percentile — below its historical average).
Cytokinetics Inc. trades below its historical valuation range, with most metrics below their median levels.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 0.08 | 0.05 | 0.09 | 0.31 | 33th | below its historical average |
Cytokinetics Inc. (CYTK) Valuation & P/E History
Cytokinetics Inc. (CYTK) is a US-listed stock operating in the Healthcare sector, specifically the Pharmaceutical Preparations industry currently trading at $67.90 with a market capitalization of $9.4 billion. This page provides historical valuation analysis for CYTK based on 500 data points covering 2024-09-24 to 2026-09-22.. The P/S ratio of 0.08 compares to a median of 0.09.
CYTK Valuation Metrics & Historical Range
The valuation table above shows Cytokinetics Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether CYTK is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests CYTK is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Cytokinetics Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is CYTK Overvalued or Undervalued?
Cytokinetics Inc. trades below its historical valuation range, with most metrics below their median levels. The overall valuation percentile of 33 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive CYTK is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full CYTK analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.CYTK trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.